A Phase 3 interventional study of SCTC21C and Bortezomib in Amyloidosis, sponsored by Sinocelltech Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Amyloidosis with a site in China — 21 open to participants now, 25 under way, 3 of them phase 3. Amyloidosis · China.
Among the 32 studies in Amyloidosis with a site in China, this one is the 7th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 3, reaches primary completion later than 11 of the 24 other live ones, and was the 29th registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →21 of the 32 studies in Amyloidosis with a site in China are open now. Recruiting first, the newest first:
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Sites in China
Ages 18–80
Peking University First Hospital · Sites in China
Ages 18–70
Gracell Biotechnologies (Shanghai) Co., Ltd. · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Keymed Biosciences Co.Ltd · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 11 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 46 across 189 interventional studies indexed under Amyloidosis.
Median enrollment 53 across the 24 interventional studies, 450 across the 8 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sinocelltech Ltd., one of the names counted as Sinocelltech Group Limited. Under that name alone:
Sinocelltech Ltd. is the lead sponsor of 82 studies on the registry; 33 are open to participants now.
Sinocelltech Group Limited has 1 study filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Amyloidosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07151690Institute of Hematology & Blood Diseases Hospital, ChinaBCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Amyloidosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of SCTC21C plus cyclophosphamide, bortezomib and dexamethasone (VCd) compared with VCd alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
This study comprises two phases: Part 1 is the safety run in, while Part 2 is a randomized, controlled, open-label, multicenter study. Both parts are divided into three stages: the screening period (up to 28 days before first dose/randomization), the treatment period (from Cycle 1 [28 days] Day 1 and continues until disease progression or unacceptable toxicity), and the follow-up period (Postintervention). Safety endpoints include treatment-emergent adverse events , treatment-related adverse events, serious adverse events, clinical laboratory tests, vital signs, physical examinations, electrocardiograms , etc. Efficacy endpoints include Overall Complete Hematologic Response (CHR),objective response rate (ORR), Hematologic Very Good Partial Response (VGPR) or Better Rate, Overall Survival (OS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SCTC21C · Drug: Bortezomib · Drug: Dexamethasone · Drug: Cyclophosphamide
Drug: Bortezomib · Drug: Dexamethasone · Drug: Cyclophosphamide
Pharmaceutical form: Solution for infusion; Route of administration: Subcutaneous
Pharmaceutical form: Lyophilized powder for injection; Route of administration: Subcutaneous
Pharmaceutical form: Tablets, ampoules or vials for injection; Route of administration: Oral/Intravenous
Pharmaceutical form: Tablets, ampoules or vials for injection; Route of administration: Oral/Intravenous
Percentage of Participants With Overall Complete Hematologic Response (CHR)
Overall CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria.
Time frame: Up to approximately 50 months after the First Participant In (FPI)
Major Organ Deterioration Progression-Free Survival (MOD-PFS)
MOD-PFS was defined as duration from the date of randomization to either hematologic progression, or major organ deterioration (clinical manifestation of cardiac failure or renal failure), or death, whichever occurred first.
Time frame: Up to approximately 50 months after the FPI
Percentage of Participants Who Achieved Complete Hematologic Response (CHR) at 6 Months
CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria.
Time frame: Month 6
Duration of Complete Hematologic Response (CHR)
Duration of CHR was defined as the time between the date of initial documentation of CHR to the date of first documented evidence of hematologic progressive diseased.
Time frame: Up to approximately 50 months after the FPI
Hematologic Very Good Partial Response (VGPR) or Better Rate
Hematologic VGPR or Better Rate was defined as percentage of participants who achieved hematologic Complete response (CR) or VGPR.
Time frame: Up to approximately 50 months after the FPI
Overall Survival (OS)
Overall survival (OS) was measured from the date of randomization to the date of the participant's death.
Time frame: Up to approximately 50 months after the FPI
Adverse Events
Treatment-emergent adverse events/serious adverse events
Time frame: Up to approximately 50 months after the FPI
PRO: EQ-5D-5L
Health state utility and health status will be assessed using the European Quality of Life Group questionnaire with 5 dimensions and 5 levels per dimension (EQ-5D-5L)
Time frame: Up to approximately 50 months after the FPI
Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.
Of 25 phase 3 interventional studies under Amyloidosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 74. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-CD38 Monoclonal Antibody SCTC21C